Results 51 to 60 of about 1,844 (180)

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review

Revista Portuguesa de Cardiologia, 2022
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, defined as a left ventricular wall thickness of ≥15 mm, in the absence of other causes of abnormal ventricular loading.
Tiago Aguiar, Elisabete Martins
doaj   +1 more source

Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten [PDF]

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disorder of the heart, but effective treatment options remain limited. Mavacamten, a direct myosin modulator, has been presented as novel pharmacological therapy for HCM.
Amesz, Jorik H., de Groot, Natasja M.S., de Jong, Peter L., Langmuur, Sanne J.J., Manintveld, Olivier C., Schinkel, Arend F.L., Taverne, Yannick J.H.J., Zhang, Lu   +7 more
core   +2 more sources

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 30-32, January 2026.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Mavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Daniel Seung Kim, Emily L. Chu, Emily E. Keamy-Minor, Ishan Dhananjay Paranjpe, Wilson L. Tang, Jack W. O’Sullivan, Jack W. O’Sullivan, Jack W. O’Sullivan, Yaanik B. Desai, Yaanik B. Desai, Michael B. Liu, Michael B. Liu, Elise Munsey, Kimberly Hecker, Isabella Cuenco, Beth Kao, Ellen Bacolor, Colleen Bonnett, Andrea Linder, Kathleen Lacar, Nancy Robles, Cindy Lamendola, Allysonne Smith, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Joshua W. Knowles, Marco V. Perez, Marco V. Perez, Marco V. Perez, Marco V. Perez, Masataka Kawana, Masataka Kawana, Masataka Kawana, Karim I. Sallam, Karim I. Sallam, Karim I. Sallam, Chad S. Weldy, Chad S. Weldy, Chad S. Weldy, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Matthew T. Wheeler, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Victoria N. Parikh, Heidi Salisbury, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, Euan A. Ashley, the Stanford Center for Inherited Cardiovascular Disease, Karim I Sallam, Masataka Kawana, Chad S Weldy, Marco Perez, Joshua W Knowles, Jason Tso, Cindy Lamendola, Allysonne Smith, Nancy Robles, Colleen Bonnett, Ellen Bacolor, Kimberly Hecker, Isabella Cuenco, Beth Kao, Elise Munsey, Andrea Linder, Kathleen Lacar, Julia Platt, Chloe Reuter, Tia Moscarello, Ryan Murtha, Jennifer Kohler, Hannah Ison, Mitchel Pariani, Anusha Klinder, Priya Nair, Jennifer Marino, Andrea Linder, Ruchi Patel, Matthew T Wheeler, Euan A Ashley, Victoria N Parikh   +92 more
doaj   +1 more source

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The phase 2 PIONEER‐HCM (Phase 2 Open‐label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular ...
Ahmad Masri, Steven J. Lester, John C. Stendahl, Sheila M. Hegde, Amy J. Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang   +8 more
doaj   +1 more source

Pharmacological Inhibition of β Myosin II Disrupts Sarcomere Assembly in Human iPSC‐Derived Cardiac Myocytes

Cytoskeleton, Volume 82, Issue 12, Page 795-803, December 2025.
ABSTRACT Sarcomeres are the fundamental contractile units of striated muscle. The functional roles of the cardiac‐specific myosin heavy chains, MYH6 (α myosin II) and MYH7 (β myosin II) during sarcomere assembly remain controversial. To address this, we utilized a selective MYH7 inhibitor, mavacamten, in combination with siRNA‐mediated knockdown of ...
James B. Hayes, Dylan T. Burnette
wiley   +1 more source

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is the first cardiac myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera   +9 more
doaj   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy.
Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi   +6 more
doaj   +1 more source